NRIX Stock: Price, Earnings History and SEC Filings
Nurix Therapeutics, Inc. (NRIX) last traded at $26.80, down 1.18% on the latest session and up 13.0% over the past month. In its most recent reported quarter (Aug 2026) earnings per share were $4.73 against an analyst estimate of $-0.56, a beat of 944.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NRIX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Aug 2026 | Oct 12, 2026 | $4.73 | $-0.56 | +944.64% |
| May 2026 | Jul 9, 2026 | $-0.81 | $-0.73 | -10.96% |
| Feb 2026 | Apr 8, 2026 | $-0.79 | $-0.76 | -3.95% |
| Nov 2025 | Jan 28, 2026 | $-0.82 | $-0.84 | +2.38% |
NRIX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How NRIX reacts to earnings
Across its last 8 earnings releases, NRIX moved 3.9% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-13 | Before open | -0.14% |
| 2026-07-09 | After close | -6.60% |
| 2026-04-08 | Before open | -4.59% |
| 2026-01-28 | After close | -1.57% |
| 2025-10-09 | After close | -10.13% |
| 2025-07-09 | After close | -3.87% |
| 2025-04-08 | After close | +3.67% |
| 2025-01-28 | After close | +0.46% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NRIX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $84M | -$264M | -$263M | -314.9% | $-3.05 |
| 2024 | $55M | -$194M | -$182M | -354.9% | $-2.88 |
| 2023 | $77M | -$144M | -$90M | -187.0% | $-2.65 |
| 2022 | $39M | -$180M | -$172M | -466.9% | $-3.71 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NRIX
- 10-Q · Oct 13, 2026
- 8-K · Oct 13, 2026Results of operations, Financial statements and exhibits
- 10-Q · Jul 9, 2026
- 8-K · Jul 9, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 11, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 8, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 15, 2026Shareholder vote, Financial statements and exhibits
- 10-Q · Apr 8, 2026
- 8-K · Apr 8, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Mar 27, 2026
Insider filing activity
NRIX insiders filed 7 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NRIX news
- Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?Oct 28, 2026 · finance.yahoo.com
- Could You Have Seen The Run In Kymera Stock Coming?Oct 26, 2026 · trefis.com
- Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesOct 22, 2026 · finance.yahoo.com
- What Nurix Therapeutics Stock's Profit Turnaround Means For ShareholdersOct 22, 2026 · finance.yahoo.com
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Oct 19, 2026 · finance.yahoo.com
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in November.